Review of NICE Technology Appraisal Guidance No. 235; Mifamurtide for the treatment of osteosarcoma

The Institute was proposing that TA235 should be moved to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

TA235 will therefore be added to the static list.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

January 2014